Guardant Health Inc (GH):企業の製品パイプライン分析2018

【英語タイトル】Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update

GlobalDataが出版した調査資料(DATA904C12779)・商品コード:DATA904C12779
・発行会社(調査会社):GlobalData
・発行日:2018年12月
・ページ数:31
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥160,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥240,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Guardant Health Inc Company Overview 4
Guardant Health Inc Company Snapshot 4
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Guardant Health Inc – Pipeline Analysis Overview 7
Guardant Health Inc – Key Facts 7
Guardant Health Inc – Major Products and Services 8
Guardant Health Inc Pipeline Products by Development Stage 9
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11
Guardant Health Inc Pipeline Products Overview 13
Anti-RSP03 Antibody Based Blood Test 13
Anti-RSP03 Antibody Based Blood Test Product Overview 13
Gene-Based Test – Lung Cancer 14
Gene-Based Test – Lung Cancer Product Overview 14
GUARDANT360 15
GUARDANT360 Product Overview 15
GUARDANT360 Clinical Trial 16
Guardant360 CDx Test – Tepotinib 18
Guardant360 CDx Test – Tepotinib Product Overview 18
Guardant360 Companion Diagnostic Assay – Glesatinib 19
Guardant360 Companion Diagnostic Assay – Glesatinib Product Overview 19
Guardant Health Inc – Key Competitors 20
Guardant Health Inc – Key Employees 21
Guardant Health Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Guardant Health Inc, Recent Developments 23
Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients 23
Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit 23
Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications 23
Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer 24
May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications 24
Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison 25
Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay 25
Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients 26
Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood 26
Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial 27
Appendix 28
Methodology 28
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Guardant Health Inc Pipeline Products by Equipment Type 5
Guardant Health Inc Pipeline Products by Indication 6
Guardant Health Inc Ongoing Clinical Trials by Trial Status 6
Guardant Health Inc, Key Facts 7
Guardant Health Inc, Major Products and Services 8
Guardant Health Inc Number of Pipeline Products by Development Stage 9
Guardant Health Inc Pipeline Products Summary by Development Stage 10
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11
Guardant Health Inc Ongoing Clinical Trials Summary 12
Anti-RSP03 Antibody Based Blood Test - Product Status 13
Anti-RSP03 Antibody Based Blood Test - Product Description 13
Gene-Based Test - Lung Cancer - Product Status 14
Gene-Based Test - Lung Cancer - Product Description 14
GUARDANT360 - Product Status 15
GUARDANT360 - Product Description 15
GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies 16
GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection 16
GUARDANT360 - Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer 16
GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) 16
GUARDANT360 - Noninvasive versus Invasive Lung Evaluation 17
GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial 17
Guardant360 CDx Test - Tepotinib - Product Status 18
Guardant360 CDx Test - Tepotinib - Product Description 18
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status 19
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description 19
Guardant Health Inc, Key Employees 21
Glossary 30

List of Figures
Guardant Health Inc Pipeline Products by Equipment Type 5
Guardant Health Inc Pipeline Products by Development Stage 9
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

★調査レポート[Guardant Health Inc (GH):企業の製品パイプライン分析2018] (コード:DATA904C12779)販売に関する免責事項を必ずご確認ください。
★調査レポート[Guardant Health Inc (GH):企業の製品パイプライン分析2018]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆